Special Issue

Anti-Infectives: Pharmacoepidemiology and Clinical Pharmacology

Message from the Guest Editors

Antibiotics are life-saving medications. Since the inception of the first antibiotic, there have been continuous and growing complexities associated with the application and development of anti-infective agents, much of which is owed to antimicrobial resistance. The pharmacoepidemiology and pharmacovigilance of various antimicrobials tend to differ between institutions, patient populations, and countries due to an innumerable number of factors. However, there is one constant: the ever-changing nature of microorganisms influenced by antimicrobials. This Special Issue aims to collect articles that consider and foreground various aspects of anti-infectives, including resistance, adverse events, epidemiology, disparities in healthcare, health policy, and best practices. As knowledge regarding antimicrobials is further disseminated, novel frameworks can be developed and compared across various institutions or communities.

Guest Editors

Dr. Lee Nguyen

Department of Clinical Pharmacy Practice, School of Pharmacy & Pharmaceutical Sciences, University of California, Irvine, CA, USA

Dr. Jason Yamaki

School of Pharmacy, Chapman University, Irvine, CA 92618, USA

Deadline for manuscript submissions

closed (31 July 2024)



Pharmacoepidemiology

an Open Access Journal by MDPI

Indexed in Scopus
Tracked for Impact Factor



mdpi.com/si/171658

Pharmacoepidemiology
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
pharmacoepidemiology@mdpi.com

mdpi.com/journal/ pharmacoepidemiology





Pharmacoepidemiology

an Open Access Journal by MDPI

Indexed in Scopus
Tracked for Impact Factor



About the Journal

Message from the Editor-in-Chief

We are very proud to launch this new, international, peer-reviewed, and open access journal. The main aim of *Pharmacoepidemiology* is to publish novel and up-to-date research findings, reviews, and communications on the beneficial effects of drugs as well as their potential adverse effects on humans through epidemiological studies conducted in the real world on large populations.

All researchers working in the pharmacoepidemiologic field—such as epidemiologists, clinical researchers, pharmacologists, clinicians, and biostatisticians—are welcome to contribute to *Pharmacoepidemiology*.

Editor-in-Chief

Dr. Carlotta Franchi

Laboratory of Pharmacoepidemiology and Human Nutrition,
Department of Health Policy, Istituto di Ricerche Farmacologiche Mario
Negri IRCCS, Milan, Italy

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within ESCI (Web of Science), Scopus and other databases.

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 21.6 days after submission; acceptance to publication is undertaken in 3.2 days (median values for papers published in this journal in the first half of 2025).

